GW Pharmaceuticals Regains Exclusive Rights to Sativex

GW Pharmaceuticals announces they now have exclusive commercialisation rights to Sativex in the UK from Bayer

GW Pharmaceuticals plc (GW) and Bayer plc, the life science company, today announce that GW will regain exclusive UK commercialisation rights for Sativex® (delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD)) from Bayer.

Sativex, often known by the USAN name nabiximols, is a complex botanical formulation that contains the principal cannabinoids THC and CBD in addition to specific minor cannabinoids and other non-cannabinoid components. Nabiximols is indicated in the treatment of spasticity due to multiple sclerosis.

Since it was approved by the Medicines and Healthcare products Regulatory Agency (MHRA) in 2010, Bayer has been responsible for the marketing of nabiximols in the UK. Under the terms of the agreement, there will be a transitional period until 31 December 2020 at which point GW will take over all responsibilities for nabiximols in the UK.

In the interim, Bayer and GW will work closely to ensure a seamless transition for health care professionals and patients, with marketing transferring to GW during 2020.

Currently, there is no change to day to day business practices and stakeholders will receive further notification when transfers and operations are expected to take place.

To learn more about GW Pharma visit their company HQ here.

Disclaimer: Past performance is not an indicator of future performance.


The UK cannabis market could be on the verge of a multi-billion-pound boom

While the majority of cannabis sold in the UK still comes from the black market, things are rapidly beginning to change.

In fact, a 2016 UN report found that the UK accounted for approximately 45% of global cannabis production, while also being responsible for 70% of the worldwide export market.

However, the UK industry is still in its infancy, which has left investors starved for British pot stocks to add to their portfolio.

And with Prohibition Partners predicting the industry could reach $3 billion in size by 2024, this is one investment opportunity you don't want to miss.

Subscribe Now
& Keep Up to Date

Get the latest pot stock recommendations, cannabis news
and industry updates straight to your inbox!

Niki Mohazeb
Niki Mohazeb

Niki is a Sydney based writer, with a passion for promoting the health benefits of medicinal cannabis. Niki also enjoys researching and writing about the future of cannabis along with the many other benefits that the plant provides, such as the diverse utilities of hemp.

Leave a Reply

Your email address will not be published. Required fields are marked *